Self-amplifying RNA (saRNA)

Revolutionizing Vaccine Development

Rapid response to emerging diseases is critical when developing a vaccine. Long RNA (mRNA and saRNA) is at the forefront of vaccine development.

Benefits of saRNA
  • saRNA vaccines can be developed in a fraction of the time it takes to develop a conventional vaccine
  • Manufacturing is cell-free, does not require a dedicated facility
  • saRNA vaccines often produce a higher immune response from a smaller dose when compared to mRNA based vaccines


Request a Sample of saRNA

Interested in a sample of saRNA? Use the link below to submit your request. If you have any other questions, please reach out to our client relations team for assisstance.


Request Sample

saRNA Inventory Products

Increase the duration and level of antigen expression for a better immune response using self-amplifying RNA technology. Aldevron offers a synthetic replicon design based on a single-stranded RNA alphavirus that expresses GFP / SEAP / LUC reporter enzyme. For research use only, easily measure the reporter gene expression in vivo to evaluate self-amplifying RNA and optimize delivery formulations in your application.

Note: saRNA products are classified by Aldevron under ECCN 1C353 on the Commerce Control List set forth in the US Export Administration Regulations (EAR), which is highly controlled for purposes of export outside the United States. If the product is requested to be shipped outside the US, an export license from US Dept. of Commerce’s Bureau of Industry and Security is required before the product may be shipped.

Pack Sizes

AldnLUC saRNA™

saRNA Quality Control Specifications

Appearance Clear and colorless
Buffer Water
Concentration 1.0 mg/mL +/- 10%
Purity Based on 260/280 Absorbance Ratio (mRNA) Report Results
Endotoxin ≤ 100 EU/mg
Identity Size Confirmed Against an RNA Ladder
Request a Complete CoA


Related News

Webinar: How a Sponsored CMC Platform Accelerates mRNA Projects to the Clinic

On the pathway to GMP manufacturing in support of clinical trials, multiple technology transfers may correlate to an increase in complexity and risk...

mRNA/saRNA Manufacturing Webinar: Considerations to Accelerate the Path to Clinic

March 22, 2022 8 am PT, 11 am ET, 16:00 CET Messenger RNA (mRNA) and self-amplifying RNA (saRNA) unravel new possibilities for the treatment and...

In the News: Aldevron's Collaboration with Ginkgo Bioworks Yields Manufacturing Breakthrough for Vaccinia Capping Enzyme Used for Manufacturing of mRNA Vaccines

Aldevron, a leading research to GMP biomanufacturer of plasmid DNA, mRNA, and proteins, and Ginkgo Bioworks, Inc. ("Ginkgo") today announced a...

Related Blog Posts

When Preparation Meets Opportunity

mRNA’s rise amidst the COVID pandemic The introduction of mRNA vaccines by Pfizer and Moderna for COVID-19 took much of the world by surprise. But...